References
- Mack U, Migliori GB, Sester M et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur. Respir. J.33, 956–973 (2009).
- Andrews JR, Noubary F, Walensky RP et al. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin. Infect. Dis.54(6), 784–791 (2012).
- Mancuso JD, Mazurek GH, Tribble D et al. Discordance among commercially-available diagnostics for latent tuberculosis infection. Am. J. Respir. Crit. Care Med.185(4), 427–434 (2012).
- Sester M, Sotgiu G, Lange C et al. Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur. Respir. J.37, 100–111 (2011).
- Palazzo R, Spensieri F, Massari M et al. Use of whole-blood samples in in-house bulk and single-cell antigen-specific γ interferon assays for surveillance of Mycobacterium tuberculosis infections. Clin. Vaccin. Immunol.15, 327–337 (2008).
- Butera O, Chiacchio T, Carrara S et al. New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response. BMC Infect. Dis.9, 182 (2009).
- Pai M, Kalantri S, Menzies D. Discordance between tuberculin skin test and interferon-γ assays. Int. J. Tuberc. Lung Dis.10, 942–943 (2006).
- Gallant CJ, Cobat A, Simkin L et al. Tuberculin skin test and in vitro assays provide complementary measures of antimycobacterial immunity in children and adolescents. Chest137, 1071–1077 (2010).
- Mancuso JD, Tribble D, Mazurek GH et al. Impact of targeted testing for latent tuberculosis infection using commercially available diagnostics. Clin. Infect. Dis.53, 234–244 (2011).
- Weir RE, Gorak-Stolinska P, Floyd S et al. Persistence of the immune response induced by BCG vaccination. BMC Infect. Dis.8, 9 (2008).
- Targeted tuberculin testing and treatment of latent tuberculosis infection. Am. J. Respir. Crit. Care Med.161, S221–S247 (2000).
- Mazurek GH, Jereb J, Vernon A et al. Updated guidelines for using interferon-γ release assays to detect Mycobacterium tuberculosis infection – United States. MMWR Recomm. Rep.59, 1–25 (2010).
- Erkens CG, Kamphorst M, Abubakar I et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur. Respir. J.36, 925–949 (2010).
- Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a whole-blood interferon-{γ} release assay for developing active tuberculosis: an update. Am. J. Respir. Crit. Care Med.183, 88–95 (2011).
- Goletti D, Butera O, Vanini V et al. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur. Respir. J.36, 135–142 (2010).
- Delogu G, Chiacchio T, Vanini V et al. Methylated HBHA produced in M. smegmatis discriminates between active and non-active tuberculosis disease among RD1-responders. PLoS ONE6, e18315 (2011).
- Goletti D, Raja A, Syed Ahamed Kabeer B et al. Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons? PLoS ONE5, e12577 (2010).
- Sester U, Fousse M, Dirks J et al. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states. PLoS ONE6, e17813 (2011).
- Leyten EM, Arend SM, Prins C et al. Discrepancy between Mycobacterium tuberculosis-specific γ interferon release assays using short and prolonged in vitro incubation. Clin. Vaccine Immunol.14, 880–885 (2007).